Millennium discloses 4.9% Avalo Therapeutics (AVTX) stake in new Schedule 13G

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. received a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 905,798 shares of Avalo common stock, representing 4.9% of the class.

The filing notes that the reporting persons exceeded 5% beneficial ownership of Avalo’s common stock on January 28, 2026, but had reduced their holdings to 4.9% by the date of the statement. Voting and investment power over these shares is reported as shared, with no sole voting or dispositive power.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

05338F306

(CUSIP Number)

01/28/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 905,798.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 905,798.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

905,798.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 905,798.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 905,798.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

905,798.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 905,798.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 905,798.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

905,798.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on January 28, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	02/02/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	02/02/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	02/02/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 2, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What does the Millennium Schedule 13G reveal about Avalo Therapeutics (AVTX)?

The Schedule 13G shows Millennium entities and Israel A. Englander report beneficial ownership of 905,798 Avalo shares, or 4.9% of the common stock. They report shared voting and dispositive power over all these shares, and no sole voting or dispositive authority.

Who are the reporting persons in the Avalo Therapeutics (AVTX) Schedule 13G?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. They file jointly, with the entities organized in Delaware and Mr. Englander a U.S. citizen, and provide a joint filing agreement as Exhibit I.

How large is Millennium’s reported stake in Avalo Therapeutics (AVTX)?

Millennium and associated reporting persons disclose 905,798 shares of Avalo common stock, representing 4.9% of the outstanding class. All reported shares are subject to shared voting and shared dispositive power, with no sole authority reported for any of the filers.

Did Millennium previously own more than 5% of Avalo Therapeutics (AVTX)?

Yes. The filing states the reporting persons acquired more than 5% beneficial ownership on January 28, 2026. By the date of the Schedule 13G, they report having reduced their beneficial ownership to 4.9% of Avalo’s outstanding common stock.

What certification do the filers make in the Avalo Therapeutics (AVTX) 13G?

They certify the securities were not acquired or held to change or influence control of Avalo and are not held in connection with any control-related transaction, other than activities solely related to a nomination under Rule 240.14a-11 as referenced in the certification language.

How is voting and investment power over Avalo (AVTX) shares described in the 13G?

For each reporting person, the filing lists 0 shares with sole voting or dispositive power and 905,798 shares with shared voting and shared dispositive power. The statement explains these shares are held by entities subject to Millennium’s and Mr. Englander’s control structures.